Johnson & Johnson Reports the P-II (SunRISe-4) Study Data of TAR-200 Plus Cetrelimab to Treat Muscle-Invasive Bladder Cancer
Shots:
- J&J reported interim data from the P-II (SunRISe-4) trial evaluating the safety & efficacy of neoadj. TAR-200 + cetrelimab vs neoadj. cetrelimab to treat MIBC patients scheduled for radical cystectomy (RC) & cannot receive neoadj. Pt-based CT at ESMO 2024
- Study showed pCR rate of 42% vs 23% in non-metastatic MIBC patients and pOR rate of 60% vs 36%. Among patients with organ-confined disease (cT2), the pCR rate was 48% vs 23%, with 68% being downstaged (≤ pT1) during RC
- TAR-200 is system for extended gemcitabine release in the bladder, enhancing local drug exposure. It was designated as breakthrough therapy by the US FDA in Dec 2023 for treating BCG-unresponsive HR-NMIBC patients who cannot undergo RC
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Janssen Reports P-II Study (SunRISe-1) Results of TAR-200 for the Treatment of Patients with BCG-Unresponsive HR-NMIBC CIS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
